Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claim accurately reflects the FDA label’s statement that it is unknown whether tirzepatide causes thyroid C-cell tumors (including MTC) in humans and that this uncertainty is based on rodent findings, supported by Sections 5.1, 13.1, and 17.
Category Scores
Accurate Statements
Unknown whether MOUNJARO causes thyroid C-cell tumors (including medullary thyroid carcinoma) in humans; based on rodent findings.
Supported by Section 5.1 ('It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans...') and corroborated by rodent findings in Section 13.1 and counseling language in Section 17.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No additional risky instructions or overstatements were made beyond accurately reflecting the label’s uncertainty about human relevance.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement